title: Validation of the NCCN-IPI in both de novo and transformed diffuse large B cell lymphoma.
authors.affiliation: a Department of Medicine , University of Toronto , Toronto , ON , Canada.
authors.forename: Jay Y
authors.initials: JY
authors.lastname: Spiegel
authors.affiliation: b Division of Hematology/Oncology, Sunnybrook , Odette Cancer Center, University of Toronto , Toronto , ON , Canada.
authors.forename: Matthew C
authors.initials: MC
authors.lastname: Cheung
authors.affiliation: b Division of Hematology/Oncology, Sunnybrook , Odette Cancer Center, University of Toronto , Toronto , ON , Canada.
authors.forename: Hany R
authors.initials: HR
authors.lastname: Guirguis
authors.affiliation: b Division of Hematology/Oncology, Sunnybrook , Odette Cancer Center, University of Toronto , Toronto , ON , Canada.
authors.forename: Rena
authors.initials: R
authors.lastname: Buckstein
mesh_terms: D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D015331:Cohort Studies; D005260:Female; D006801:Humans; D007390:International Agencies; D053208:Kaplan-Meier Estimate; D016403:Lymphoma, Large B-Cell, Diffuse / Q000175:diagnosis / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D017063:Outcome Assessment, Health Care / Q000379:methods*; D017410:Practice Guidelines as Topic; D011379:Prognosis; D015203:Reproducibility of Results